王建華

摘要：目的? 以Meta分析的方法來(lái)評(píng)價(jià)利妥昔單抗聯(lián)合CHOP方案治療B細(xì)胞性非霍奇金淋巴瘤的療效。方法? 計(jì)算機(jī)檢索維普數(shù)據(jù)庫(kù)、中國(guó)知網(wǎng)、萬(wàn)方數(shù)據(jù)庫(kù)、pubmed數(shù)據(jù)庫(kù)等，檢索利妥昔單抗聯(lián)合化療治療B細(xì)胞性非霍奇金淋巴瘤的隨機(jī)對(duì)照試驗(yàn)，并手工檢索相關(guān)會(huì)議記錄及紙質(zhì)文獻(xiàn)，應(yīng)用國(guó)際Cochrane協(xié)作網(wǎng)的系統(tǒng)評(píng)價(jià)方法對(duì)所得數(shù)據(jù)進(jìn)行質(zhì)量評(píng)分，進(jìn)行資料提取后，采用RevMan5.3軟件進(jìn)行Meta分析。結(jié)果? 共檢索到14個(gè)隨機(jī)對(duì)照試驗(yàn)，共包括2433例患者，異質(zhì)性檢驗(yàn)P>0.1，基線(xiàn)具有可比性，選擇固定效應(yīng)模型分析所得結(jié)果顯示R-CHOP方案化療組的完全緩解率高于單純CHOP化療組（RR=1.3，95%CI為1.3～1.41），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;R-CHOP方案總有效率高于CHOP組（RR=1.32，95%CI為1.22～1.42），差異有統(tǒng)計(jì)學(xué)意義（P<0.05）;其不良反應(yīng)與對(duì)照組比較，差異無(wú)統(tǒng)計(jì)學(xué)意義（P>0.05）。結(jié)論? R-CHOP方案相對(duì)CHOP方案治療B細(xì)胞性非霍奇金淋巴瘤來(lái)說(shuō)具有更高的完全緩解率和總有效率，進(jìn)一步證明其治療效果需開(kāi)展更多的隨機(jī)對(duì)照試驗(yàn)。

關(guān)鍵詞：B細(xì)胞性非霍奇金淋巴瘤;利妥昔單抗;隨機(jī)對(duì)照試驗(yàn)

中圖分類(lèi)號(hào)：R551.2? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?文獻(xiàn)標(biāo)識(shí)碼：A? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?DOI：10.3969/j.issn.1006-1959.2019.10.027

文章編號(hào)：1006-1959（2019）10-0081-04

Abstract：Objective? To evaluate the efficacy of rituximab combined with CHOP regimen in the treatment of B-cell non-Hodgkin's lymphoma by meta-analysis.Methods? A computer-based search of the Vip database， China Knowledge Network， Wanfang database， pubmed database， etc.， search for randomized controlled trials of rituximab combined with chemotherapy for B-cell non-Hodgkin's lymphoma， and manually retrieve relevant meeting minutes and paper In the literature， the systematic evaluation method of the international Cochrane Collaboration Network was used to score the quality of the data，after data extraction， Meta analysis was performed using RevMan5.3 software.Results? A total of 14 randomized controlled trials were included， including a total of 2，433 patients. The heterogeneity test was P>0.1， and the baseline was comparable. The results of the selected fixed-effects model showed that the complete response rate of the R-CHOP regimen was higher than that of CHOP alone. The chemotherapy group （RR=1.3， 95% CI 1.3～1.41）， the difference was statistically significant （P<0.05）; the total effective rate of R-CHOP regimen was higher than that of CHOP group （RR=1.32， 95% CI was 1.22～1.42），the difference was statistically significant（P<0.05）; the adverse reactions were not significantly different from the control group（P>0.05）.Conclusion? The R-CHOP regimen has a higher complete response rate and total effective rate than the CHOP regimen in the treatment of B-cell non-Hodgkin's lymphoma.It is further proved that the therapeutic effect requires more randomized controlled trials.